Bio-X


Showing 931-940 of 1,058 Results

  • Yuri Suzuki

    Yuri Suzuki

    Professor of Applied Physics and, by courtesy, of Materials Science and Engineering

    Current Research and Scholarly InterestsHer interests are focused on novel ground states and functional properties in condensed matter systems synthesized via atomically precise thin film deposition techniques with a recent emphasis has been on highly correlated electronic systems:
    • Emergent interfacial electronic & magnetic phenomena through complex oxide heteroepitaxy
    • Low dimensional electron gas systems
    • Spin current generation, propagation and control in complex oxide-based ferromagnets
    • Multifunctional behavior in complex oxide thin films and heterostructures

  • Katrin J Svensson

    Katrin J Svensson

    Assistant Professor of Pathology

    Current Research and Scholarly InterestsMolecular metabolism
    Protein biochemistry
    Cell biology and function
    Animal physiology

  • James Swartz

    James Swartz

    James H. Clark Professor in the School of Engineering and Professor of Chemical Engineering and of Bioengineering

    Current Research and Scholarly InterestsProgram Overview

    The world we enjoy, including the oxygen we breathe, has been beneficially created by biological systems. Consequently, we believe that innovative biotechnologies can also serve to help correct a natural world that non-natural technologies have pushed out of balance. We must work together to provide a sustainable world system capable of equitably improving the lives of over 10 billion people.
    Toward that objective, our program focuses on human health as well as planet health. To address particularly difficult challenges, we seek to synergistically combine: 1) the design and evolution of complex protein-based nanoparticles and enzymatic systems with 2) innovative, uniquely capable cell-free production technologies.
    To advance human health we focus on: a) achieving the 120 year-old dream of producing “magic bullets”; smart nanoparticles that deliver therapeutics or genetic therapies only to specific cells in our bodies; b) precisely designing and efficiently producing vaccines that mimic viruses to stimulate safe and protective immune responses; and c) providing a rapid point-of-care liquid biopsy that will count and harvest circulating tumor cells.
    To address planet health we are pursuing biotechnologies to: a) inexpensively use atmospheric CO2 to produce commodity biochemicals as the basis for a new carbon negative chemical industry, and b) mitigate the intermittency challenges of photovoltaic and wind produced electricity by producing hydrogen either from biomass sugars or directly from sunlight.
    More than 25 years ago, Professor Swartz began his pioneering work to develop cell-free biotechnologies. The new ability to precisely focus biological systems toward efficiently addressing new, “non-natural” objectives has proven tremendously useful as we seek to address the crucial and very difficult challenges listed above. Another critical feature of the program is the courage (or naivete) to approach important objectives that require the development and integration of several necessary-but- not-sufficient technology advances.

  • Karl G. Sylvester

    Karl G. Sylvester

    Professor of Surgery (Pediatric Surgery)

    Current Research and Scholarly InterestsScholarly interests include investigation of molecular markers of human disease that provide diagnostic function, serve as targets for possible therapeutic manipulation, or provide insight into mechanisms of human disease. Specific diseases of interest include common conditions of pregnancy, gut microbial ecology and Necrotizing Enterocolitis (NEC).

  • Daniel Sze, MD, PhD

    Daniel Sze, MD, PhD

    Professor of Radiology (Interventional Radiology)

    Current Research and Scholarly InterestsTransarterial administration of chemotherapeutics, radioactive microspheres, and biologics for the treatment of unresectable tumors; management of portal hypertension and complications of cirrhosis (TIPS); treatment of complications of organ transplantation; Venous and pulmonary arterial thrombolysis and reconstruction; Stent and Stent-graft treatment of peripheral vascular diseases, aneurysms, aortic dissections

  • Christopher N. Ta, MD

    Christopher N. Ta, MD

    Professor of Ophthalmology

    BioChristopher N. Ta, MD specializes in the diagnosis and medical treatment of cornea diseases. His areas of expertise are in the treatment of ocular infections, inflammation, dry eyes and ocular surface diseases. He has conducted numerous clinical trials toward the prevention and treatment of ocular infections. Dr. Ta also has extensive clinical experience in the treatment of ocular graft-versus host disease following hematopoietic stem cell transplantation.

  • William Talbot

    William Talbot

    Mary and Dr. Salim Shelby Professor

    Current Research and Scholarly InterestsWe use genetic and cellular approaches to investigate the molecular basis of glial development and myelination in the zebrafish.

  • Longzhi Tan

    Longzhi Tan

    Assistant Professor of Neurobiology

    Current Research and Scholarly InterestsThe Tan Lab studies the single-cell 3D genome architectural basis of neurodevelopment and aging by developing the next generation of in vivo multi-omic assays and algorithms, and applying them to the human and mouse cerebellum.

  • Hua Tang

    Hua Tang

    Professor of Genetics and, by courtesy, of Statistics

    Current Research and Scholarly InterestsDevelop statistical and computational methods for population genomics analyses; modeling human evolutionary history; genetic association studies in admixed populations.

  • Jean Y. Tang MD PhD

    Jean Y. Tang MD PhD

    Professor of Dermatology

    Current Research and Scholarly InterestsMy research focuses on 2 main areas:

    1. Skin cancer:
    - New therapeutics to treat and prevent non-melanoma skin cancer, especially by targeting the Hedgehog signaling pathway for BCC tumors
    - Genomic analysis of drug-resistant cancers
    - Identifying risk factors for skin cancer in the Women's Health Initiative

    2. Epidermolysis Bullosa: gene therapy and protein therapy to replace defective/absent Collagen 7 in children and adults with Recessive Dystrophic EB